Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
DIVIS LABORATORIES | IPCA LABS | DIVIS LABORATORIES/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 49.9 | 21.7 | 229.6% | View Chart |
P/BV | x | 13.4 | 7.8 | 171.6% | View Chart |
Dividend Yield | % | 0.5 | 0.2 | 293.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
IPCA LABS Mar-19 |
DIVIS LABORATORIES/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 1,042 | 157.3% | |
Low | Rs | 1,115 | 590 | 189.0% | |
Sales per share (Unadj.) | Rs | 186.3 | 298.6 | 62.4% | |
Earnings per share (Unadj.) | Rs | 51.0 | 35.0 | 145.6% | |
Cash flow per share (Unadj.) | Rs | 57.3 | 49.4 | 115.9% | |
Dividends per share (Unadj.) | Rs | 16.00 | 3.00 | 533.3% | |
Dividend yield (eoy) | % | 1.2 | 0.4 | 316.0% | |
Book value per share (Unadj.) | Rs | 261.8 | 247.1 | 105.9% | |
Shares outstanding (eoy) | m | 265.47 | 126.35 | 210.1% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 7.4 | 2.7 | 270.5% | |
Avg P/E ratio | x | 27.0 | 23.3 | 115.9% | |
P/CF ratio (eoy) | x | 24.0 | 16.5 | 145.6% | |
Price / Book Value ratio | x | 5.3 | 3.3 | 159.3% | |
Dividend payout | % | 31.4 | 8.6 | 366.3% | |
Avg Mkt Cap | Rs m | 365,592 | 103,108 | 354.6% | |
No. of employees | `000 | 11.8 | 13.4 | 88.1% | |
Total wages/salary | Rs m | 5,423 | 7,874 | 68.9% | |
Avg. sales/employee | Rs Th | 4,175.1 | 2,807.0 | 148.7% | |
Avg. wages/employee | Rs Th | 457.7 | 585.8 | 78.1% | |
Avg. net profit/employee | Rs Th | 1,141.8 | 329.0 | 347.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 37,732 | 131.1% | |
Other income | Rs m | 1,556 | 577 | 269.8% | |
Total revenues | Rs m | 51,019 | 38,309 | 133.2% | |
Gross profit | Rs m | 18,718 | 6,901 | 271.3% | |
Depreciation | Rs m | 1,689 | 1,824 | 92.6% | |
Interest | Rs m | 35 | 189 | 18.5% | |
Profit before tax | Rs m | 18,551 | 5,465 | 339.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 5,023 | 1,042 | 481.9% | |
Profit after tax | Rs m | 13,527 | 4,422 | 305.9% | |
Gross profit margin | % | 37.8 | 18.3 | 206.9% | |
Effective tax rate | % | 27.1 | 19.1 | 142.0% | |
Net profit margin | % | 27.3 | 11.7 | 233.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 23,778 | 195.6% | |
Current liabilities | Rs m | 8,468 | 10,975 | 77.2% | |
Net working cap to sales | % | 76.9 | 33.9 | 226.6% | |
Current ratio | x | 5.5 | 2.2 | 253.5% | |
Inventory Days | Days | 131 | 104 | 126.1% | |
Debtors Days | Days | 86 | 66 | 130.2% | |
Net fixed assets | Rs m | 25,797 | 20,368 | 126.7% | |
Share capital | Rs m | 531 | 253 | 210.1% | |
"Free" reserves | Rs m | 68,962 | 30,971 | 222.7% | |
Net worth | Rs m | 69,493 | 31,224 | 222.6% | |
Long term debt | Rs m | 0 | 1,409 | 0.0% | |
Total assets | Rs m | 80,383 | 45,507 | 176.6% | |
Interest coverage | x | 531.0 | 30.0 | 1,772.5% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.8 | 74.2% | |
Return on assets | % | 16.9 | 10.1 | 166.5% | |
Return on equity | % | 19.5 | 14.2 | 137.4% | |
Return on capital | % | 26.7 | 17.3 | 154.4% | |
Exports to sales | % | 0 | 45.9 | 0.0% | |
Imports to sales | % | 24.6 | 16.6 | 148.4% | |
Exports (fob) | Rs m | NA | 17,308 | 0.0% | |
Imports (cif) | Rs m | 12,187 | 6,266 | 194.5% | |
Fx inflow | Rs m | 41,238 | 17,308 | 238.3% | |
Fx outflow | Rs m | 12,405 | 6,266 | 198.0% | |
Net fx | Rs m | 28,833 | 11,042 | 261.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | 4,923 | 193.9% | |
From Investments | Rs m | -6,854 | -1,563 | 438.5% | |
From Financial Activity | Rs m | -2,459 | -1,832 | 134.2% | |
Net Cashflow | Rs m | 230 | 1,528 | 15.0% |
Indian Promoters | % | 52.0 | 45.9 | 113.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 11.8 | 11.4 | 103.5% | |
FIIs | % | 19.0 | 25.3 | 75.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.2 | 17.4 | 98.9% | |
Shareholders | 31,796 | 36,892 | 86.2% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare DIVIS LABORATORIES With: GLENMARK PHARMA FULFORD INDIA ORCHID PHARMA BIOCON UNICHEM LAB
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More